A Study on the Different Types of Breast Carcinoma in a Tertiary Care Centre with Immunohistochemical and Molecular Correlation
Keywords:
Breast carcinoma, Immunohistochemistry, Molecular subtyping, HER2, Tertiary careAbstract
Background: Breast carcinoma represents a heterogeneous group of malignancies with diverse histological and molecular characteristics that significantly impact clinical management. Current diagnostic approaches integrate histopathological evaluation with immunohistochemical (IHC) profiling and molecular analysis to enable precise classification and personalized treatment strategies. This study aimed to characterize breast carcinoma subtypes in a tertiary care setting through comprehensive pathological and molecular correlation.
Methods: A prospective observational study was conducted on 30 histologically confirmed breast carcinoma cases. Clinicopathological parameters were recorded, and tumors were classified using WHO criteria. IHC analysis evaluated ER, PR, HER2/neu, and Ki-67 expression according to ASCO/CAP guidelines. HER2-equivocal cases underwent FISH confirmation. Molecular subtyping categorized tumors as Luminal A, Luminal B, HER2-enriched, or triple-negative. Statistical analysis included descriptive statistics and chi-square tests.
Results: The cohort demonstrated characteristic age distribution (60% patients aged 40-60 years) with predominance of invasive ductal carcinoma (80%). IHC profiling revealed ER positivity in 60%, PR in 50%, and HER2 overexpression in 16.7% of cases. Molecular subtyping identified Luminal B (33.3%) as most frequent, followed by Luminal A (26.7%) and triple-negative (26.7%) subtypes. FISH analysis resolved 50% of HER2-equivocal cases as positive. Significant associations emerged between molecular subtypes and tumor grade (p<0.05), with aggressive subtypes showing higher-grade morphology.
Conclusion: This study highlights the importance of integrated pathological and molecular characterization in breast carcinoma management. The observed predominance of Luminal B and triple-negative subtypes, along with their association with higher tumor grades, underscores the need for tailored therapeutic approaches. Findings emphasize the critical role of comprehensive biomarker testing, particularly in resolving diagnostically challenging cases, to optimize treatment strategies in diverse patient populations
Downloads
Metrics
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23.
Tan PH, Ellis I, Allison K, et al. The 2019 WHO Classification of Tumours of the Breast. Histopathology. 2020;77(2):181-5.
Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-22.
DeSantis CE, Bray F, Ferlay J, et al. International Variation in Female Breast Cancer Incidence and Mortality Rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495-506.
Agarwal G, Ramakant P. Breast Cancer Care in India: The Current Scenario and the Challenges for the Future. Breast Care (Basel). 2008;3(1):21-7.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346-66.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi:10.3322/caac.21660.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-10. doi:10.1111/j.1365-2559.1991.tb00229.x.
Giordano SH. Breast cancer in men. N Engl J Med. 2018;378(24):2311-20. doi:10.1056/NEJMra1707939.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95. doi:10.1200/JCO.2009.25.6529.
Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973-9. doi:10.1200/JCO.2003.09.099.
Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-22. doi:10.1200/JCO.2018.77.8738.
Perez EA, Cortés J, Gonzalez-Angulo AM, et al. HER2 testing: current status and future directions. Cancer Treat Rev. 2014;40(2):276-84. doi:10.1016/j.ctrv.2013.09.001.
Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174-83. doi:10.1016/S1470-2045(09)70262-1.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. doi:10.1038/35021093.
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34. doi:10.1158/1078-0432.CCR-06-3045.
Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23 Suppl 6:vi7-12. doi:10.1093/annonc/mds187.
Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-8. doi:10.1200/JCO.2007.15.5986.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502. doi:10.1001/jama.295.21.2492.
Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-50. doi:10.1093/jnci/djp082.
Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-36. doi:10.1056/NEJMoa1607303.
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-21. doi:10.1056/NEJMoa1809615.
Agarwal G, Ramakant P, Forgach ER, et al. Breast cancer care in developing countries. World J Surg. 2009;33(10):2069-76. doi:10.1007/s00268-009-0150-z.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
